Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Silver Lining: Top Tech Talent Takes A Closer Look At Pharma

Executive Summary

A survey of 2,500 technology professionals across five countries conducted by Novartis finds technology talent wants to work in health care and pharma more now than before the pandemic.

You may also be interested in...



COVID-19 Pandemic Turns Big Pharma Rivals Into Bedfellows

Industry leaders at a PhRMA briefing talked about the unprecedented level of partnership going into developing COVID-19 vaccines and treatments – not to mention making enough of them.

Pandemic Is Enabling Faster Business Transformation, Says Novartis Digital Leader

Novartis has accelerated its digital ambitions during the worldwide lockdown period, working with partners such as Doximity on engaging doctors and Science 37 on virtual trial tech.

Enhertu Poised To Rewrite The Standard Of Care After ESMO

AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142473

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel